Prognostic Utility of Total (68)Ga-DOTATATE-Avid Tumor Volume in Patients with Neuroendocrine Tumors

BACKGROUND & AIMS: Survival times vary among patients with neuroendocrine tumors (NETs)—even among those with the same site, stage, and grade of primary tumor. This makes it difficult to select treatment for patients with unresectable NETs, because some patients can survive decades without treat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Gastroenterology
Glavni autori: Tirosh, Amit, Papadakis, Georgios Z., Millo, Corina, Hammoud, Dima, Sadowski, Samira M., Herscovitch, Peter, Pacak, Karel, Marx, Stephen J., Yang, Lily, Nockel, Pavel, Shell, Jasmine, Green, Patience, Keutgen, Xavier M., Patel, Dhaval, Nilubol, Naris, Kebebew, Electron
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5847442/
https://ncbi.nlm.nih.gov/pubmed/29155309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.gastro.2017.11.008
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items